Ultragenyx (RARE) officer covers RSU taxes with stock sale and award

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. officer John Richard Pinion reported stock-based compensation activity and a related tax sale. On March 1, 2026, he acquired 11,137 shares of common stock at $0.00 per share through the conversion of previously granted performance stock units after certification of performance metrics.

On March 2, 2026, he sold 10,029 common shares in an open-market transaction at a weighted average price of $22.80 per share, in multiple trades between $22.54 and $23.11, to pay required tax withholdings tied to RSU vesting. Following these transactions, he directly owned 110,026 common shares, including 490 shares from the employee stock purchase plan and shares underlying RSUs subject to vesting conditions.

Insider Trade Summary

Net Seller: 10,029 shares ($228,661)

Net Sell 2 txns

Insider Pinion John Richard

Role See Remarks

Sold 10,029 shs ($229K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,029	$22.80	$229K
Grant/Award	Common Stock	11,137	$0.00	--

Holdings After Transaction: Common Stock — 110,026 shares (Direct)

Footnotes (1)

Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics. Represents shares sold to pay required tax withholdings due to the vesting of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 07:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinion John Richard

(Last)

(First)

(Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO

94949

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/01/2026		A		11,137⁽¹⁾	A	$0	119,565	D
Common Stock	03/02/2026		S		10,029⁽²⁾	D	$22.8⁽³⁾	110,026⁽⁴⁾⁽⁵⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.

2. Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range

4. Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025

5. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Remarks:

EVP, Chief Quality Operations Officer

	/s/ Karah Parschauer, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Ultragenyx (RARE) officer John Richard Pinion report?

He reported an equity award and a related tax sale. Pinion received 11,137 Ultragenyx common shares from performance stock units, then sold 10,029 shares in the market to cover required tax withholdings from RSU vesting, according to the Form 4 details and footnotes.

How many Ultragenyx (RARE) shares did John Richard Pinion acquire and at what price?

Pinion acquired 11,137 Ultragenyx common shares at $0.00 per share. These shares came from previously granted performance stock units that converted into common stock on March 1, 2026, after performance metrics were certified, reflecting stock-based compensation rather than a cash purchase.

How many Ultragenyx (RARE) shares did John Richard Pinion sell and why?

He sold 10,029 Ultragenyx common shares. Footnotes state the sale was specifically to pay required tax withholdings triggered by the vesting of restricted stock units, meaning it functioned as a tax-cover transaction rather than a discretionary reduction of his overall equity exposure.

What price did Ultragenyx (RARE) shares sell for in John Richard Pinion’s tax-cover transaction?

The reported weighted average sale price was $22.80 per share. Footnotes explain the 10,029 shares were sold in multiple trades at prices ranging from $22.54 to $23.11, and that detailed price breakdowns are available on request from the reporting person.

How many Ultragenyx (RARE) shares does John Richard Pinion own after these transactions?

After the award and subsequent tax-related sale, Pinion directly owned 110,026 Ultragenyx common shares. This total includes 490 shares acquired under the company’s employee stock purchase plan and shares underlying restricted stock units that remain subject to vesting conditions.

What types of equity awards are mentioned in John Richard Pinion’s Ultragenyx (RARE) Form 4?

The filing references performance stock units and restricted stock units. Performance stock units converted into 11,137 common shares when performance metrics were certified, while vested restricted stock units triggered required tax withholdings, which Pinion satisfied by selling 10,029 common shares in the open market.